Medindia

X

Sinovac Filed Its Annual Report on Form 20-F for 2009

Friday, April 16, 2010 General News J E 4
Advertisement

BEIJING, April 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today it filed its annual report on Form 20-F for the fiscal year ended December 31, 2009 with the Securities and Exchange Commission on April 16, 2010. The annual report on Form 20-F can be accessed on Sinovac's website at http://www.sinovac.com/Investors/SECFilings/ . Sinovac will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    For further information, please contact:

    Sinovac Biotech Ltd.
     Helen G. Yang
     Tel:  +86-10-8289-0088 x9871
     Fax:  +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media
     Janine McCargo
     The Ruth Group
     Tel:    +1-656-536-7033
     Email:  jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Connectyx to Host Nationwide Teleconference on Wed...
S
VisEn's Announces Multi-Species FMT Imaging Expans...